Cargando…

Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms

Polypharmacy, potentially inappropriate medications (PIMs), and drug-to-drug interactions (DDIs) are highly prevalent in the elderly and may have adverse effects on health-related outcomes. Their occurrence and clinical and prognostic associations in patients with chronic myeloproliferative neoplasm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krečak, Ivan, Pivac, Ljerka, Lucijanić, Marko, Skelin, Marko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215953/ https://www.ncbi.nlm.nih.gov/pubmed/37238972 http://dx.doi.org/10.3390/biomedicines11051301

Ejemplares similares

PB2219: POLYPHARMACY AND DRUG-TO-DRUG INTERACTIONS MAY HAVE A NEGATIVE EFFECT ON SURVIVAL IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

PB2188: PROTON PUMP INHIBITORS ARE SAFE AND EFFECTIVE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA TREATED WITH LOW-DOSE ASPIRIN
por: Krecak, Ivan, et al.
Publicado: (2023)

Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study
por: Holik, Hrvoje, et al.
Publicado: (2023)

P1051: CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism
por: Lucijanic, Marko, et al.
Publicado: (2021)

Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients
por: Chen, Zhaoyan, et al.
Publicado: (2023)

PB2194: HIGHER JAK2 ALLELE BURDEN IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS IS ASSOCIATED WITH HIGHER PREVALENCE OF CHRONIC KIDNEY DISEASE AND UNFAVORABLE DYNAMICS OF KIDNEY FUNCTION OVER TIME
por: Lucijanic, Marko, et al.
Publicado: (2023)

The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy
por: Guillot, Jordan, et al.
Publicado: (2020)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

Duffy‐null erythrocyte phenotype and the risk of thrombotic events in essential thrombocythemia
por: Krecak, Ivan, et al.
Publicado: (2023)

Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment
por: Ramsdale, Erika, et al.
Publicado: (2022)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Survival analysis, more than meets the eye
por: Lucijanic, Marko, et al.
Publicado: (2017)

Polypharmacy and Potentially Inappropriate Medications in Patients With Dementia
por: Nonaka, Ryo, et al.
Publicado: (2020)

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders
por: Wolff, Jan, et al.
Publicado: (2021)

A Survey on Polypharmacy and Use of Inappropriate Medications
por: Rambhade, Sujit, et al.
Publicado: (2012)

Polypharmacy and Potentially Inappropriate Medication Use as the Precipitating Factor in Readmissions to the Hospital
por: Sehgal, Vishal, et al.
Publicado: (2013)

Irrational polypharmacy and potentially inappropriate medications in patients with dementia: Treatment strategies
por: Štuhec, M.
Publicado: (2023)

Polypharmacy, potentially serious clinically relevant drug‐drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life
por: AL‐Musawe, Labib, et al.
Publicado: (2020)

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
por: Barbui, Tiziano, et al.
Publicado: (2022)

Polypharmacy and potential drug–drug interactions in emergency department patients in the Caribbean
por: Dookeeram, Darren, et al.
Publicado: (2017)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Impact of Polypharmacy, Drug-Related Problems, and Potentially Inappropriate Medications in Geriatric Patients and Its Implications for Bulgaria—Narrative Review and Meta-Analysis
por: Krustev, Tzvetan, et al.
Publicado: (2022)

Leading 20 drug–drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients
por: Das, Biswadeep, et al.
Publicado: (2021)

Polypharmacy and potentially inappropriate medications (PIMs) in older adults referred to a memory clinic
por: Akpan, Anietie, et al.
Publicado: (2021)

Potentially Inappropriate Medication and Polypharmacy in Nursing Home Residents: A Cross-Sectional Study
por: Díez, Raquel, et al.
Publicado: (2022)

Polypharmacy and potential drug–drug interactions among Greenland’s care home residents
por: Albertsen, Nadja, et al.
Publicado: (2022)

Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients
por: Kilit, Türkan Paşalı, et al.
Publicado: (2022)

Chronic Myeloproliferative Neoplasms: a Collaborative Approach
por: Pieri, Lisa, et al.
Publicado: (2010)

Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm
por: Zielinska, Patrycja, et al.
Publicado: (2014)

Chronic Myeloproliferative Neoplasms: Some Remaining Challenges
por: Mughal, Tariq I., et al.
Publicado: (2018)

Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms
por: Marin Oyarzún, Cecilia P., et al.
Publicado: (2019)

PB2201: ASSOCIATION OF HIGH PLATELETCRIT WITH THROMBOTIC RISK IN POLYCYTHEMIA VERA DEPENDS ON HEMATOCRIT AND LEUKOCYTE COUNT
por: Krecak, Ivan, et al.
Publicado: (2023)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5jidu8pb5embfkrb2sdg3ef9dr